I am a Senior Scientist within the Cancer Translational Research Group at the Melanoma Institute Australia and an Associate Professor at the University of Sydney. My work bridges molecular discovery and clinical application through close collaboration with clinical teams and patient groups to address unmet needs and improve outcomes for people with melanoma.

My research integrates clinicopathology, genomics, gene expression profiling, and high‑dimensional spatial pathology to develop tools that guide treatment selection and advance our understanding of immunotherapy resistance. My scientific expertise spans genomic drivers of cancer development, genomic and immune correlates of patient outcomes, mechanisms of response and resistance to immunotherapy, implementation of personalised biomarker‑driven medicine, spatial pathology, and multi‑omic integration.

I lead major translational programs including the Personalised Immunotherapy Program (PIP), a world‑first precision immunotherapy initiative delivering real‑time biomarker reports to clinicians, and I have helped drive several large international research efforts such as the Australian Melanoma Genome Project. My work has contributed to high‑impact publications across Nature, Cancer Cell, Nature Communications, Cell Reports, and Clinical Cancer Research, and has been recognised with the NSW Premier’s Award for outstanding cancer research multiple times.

Across my career, I have advanced biomarker discovery, pioneered spatial pathology approaches, expanded understanding of immune responses to cancer, and led key translational studies within international clinical trials, building global collaborations that continue to shape precision oncology.